Heritage Oak Wealth Advisors LLC Invests $2.34 Million in Humana Inc. (NYSE:HUM)

Heritage Oak Wealth Advisors LLC acquired a new position in Humana Inc. (NYSE:HUM) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 9,232 shares of the insurance provider’s stock, valued at approximately $2,342,000. Humana makes up 1.1% of Heritage Oak Wealth Advisors LLC’s portfolio, making the stock its 18th largest position.

A number of other hedge funds have also made changes to their positions in the stock. Transcend Capital Advisors LLC lifted its holdings in shares of Humana by 399.7% during the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock valued at $924,000 after buying an additional 2,914 shares during the last quarter. FNY Investment Advisers LLC increased its stake in shares of Humana by 6,647.5% in the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after purchasing an additional 26,856 shares during the period. Retirement Systems of Alabama lifted its position in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares during the last quarter. PDT Partners LLC boosted its stake in Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after purchasing an additional 2,660 shares during the period. Finally, Secure Asset Management LLC acquired a new stake in Humana in the 4th quarter valued at approximately $244,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 1.6 %

NYSE:HUM opened at $255.06 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business’s 50-day simple moving average is $270.12 and its 200-day simple moving average is $288.06. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock has a market capitalization of $30.77 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.39%. Humana’s dividend payout ratio is presently 35.58%.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.32% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on HUM. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Barclays upped their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Finally, TD Cowen raised their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.